Identicare Ltd 매각
DESJARDINS RI USA 저탄소 지수 ETF 단위
$38.03
11:15 14/05/24
동물보호그룹 PLC
("회사" 또는 "그룹")
Identicare Ltd 매각
Material value creation for shareholders from non-core asset
28 2월 2024. Animalcare Group plc, the international animal health business, announces that it has disposed of its majority shareholding in Identicare Ltd ("Identicare") to BG Bidco 21 Limited, a newly incorporated company owned by funds managed by Bridgepoint Advisors II Limited, for a cash consideration of £24.9m (the "Consideration") payable upon completion of this sale. This represents a significant crystallisation of value for the Company and its shareholders from a non-core asset and allows the Company to focus on growth in its pharmaceutical-based animal health market.
Identicare is a UK-based pet microchipping and pet owner-focused services company. As part of the Group's strategy to focus on pharmaceuticals and to drive growth through launching innovative products, Identicare was separated from the UK pharmaceuticals business within Animalcare Ltd in March 2021, with specialist leadership brought in. The decisions taken by the Company to instil new leadership and with this, a strategic repositioning of the business to make it attractive to specialist investors has enabled Animalcare to today crystallise the value of its investment in Identicare.
Upon receipt of the Consideration and after fees associated with the transaction, the Company's net cash is expected to be around £27.0m.
The disposal of Identicare significantly strengthens the balance sheet of the Group and enables us to accelerate our organic and inorganic growth initiatives and deliver long-term value creation for shareholders. We continue to see a large number of opportunities and this transaction increases our confidence in being able to execute on that pipeline.
The Company expects to announce its preliminary unaudited results on 9 April 2024 and will announce further updates to its business development and capital allocation strategies at that time.
As of 31 December 2023, Identicare had net liabilities of approximately £6.9m and for the 12 months to 31 December 2023, an EBITDA* of approximately £1.7m and profit before tax of approximately £0.1m.
CEO인 Jenny Winter는 다음과 같이 말했습니다. "I'm very proud to see what we have achieved with Identicare in recent years. Today's decision to crystallise the value from the sale is the logical next step, significantly strengthening our balance sheet and giving us additional financial flexibility and firepower as we concentrate on growing our pharmaceutical-focused animal health business."
노트
Identicare financials are taken from December management accounts and are unaudited.
* EBITDA is defined as earnings before interest, tax, depreciation, amortisation, exceptional items and share based payments.
동물보호에 대해
Animalcare Group plc는 영국 AIM에 등재된 국제 수의 판매 및 마케팅 조직입니다. Animalcare는 40개국에서 운영되고 있으며 유럽 및 전 세계의 약 XNUMX개국에 수출하고 있습니다. 그룹은 자체 개발 파이프라인, 파트너십 및 인수를 통해 새롭고 혁신적인 제품을 시장에 출시하는 데 중점을 두고 있습니다.
Animalcare에 대한 자세한 내용은 www.animalcaregroup.com을 방문하거나 다음 연락처로 문의하십시오.
애니멀케어 그룹 plc 제니 윈터, 최고 경영자 크리스 브루스터(Chris Brewster), 최고재무책임자(CFO) 미디어/투자자 관계
| +44 (0)1904 487 687
|
스티펠 니콜라우스 유럽 제한 벤 매디슨 니콜라스 할랜드 프랜시스 노스
| +44 (0)20 7710 7600 |
판 뮤어 고든 (관절 Broker) 기업 금융 프레디 크로슬리/엠마 얼 기업 중개 루퍼트 디어든
| +44 (0)20 7886 2500 |
RNS는 귀하의 IP 주소를 사용하여 약관 준수 여부를 확인하고, 귀하가 이 커뮤니케이션에 포함된 정보를 사용하는 방식을 분석하고, 그러한 분석을 익명으로 다른 사람과 상용 서비스의 일부로 공유할 수 있습니다. RNS와 런던 증권 거래소가 귀하가 제공한 개인 데이터를 사용하는 방법에 대한 자세한 내용은 개인 정보 보호 정책을 참조하십시오.